You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023204014
Dec 20235504
Jan 20245206
Feb 20244005
Mar 20245001
Apr 20243202
May 20242801
Jun 20241200
Jul 20241603
Aug 20241601
Sep 20242603
Oct 20241000
Nov 202452011
Dec 20242804
Jan 20254203
Feb 2025602
Mar 2025001
Apr 2025001
May 2025002
Jun 2025102
Total670066